A prospective, randomized, double-blind, placebo-controlled study of the platelet and global hemostatic effects of Ganoderma lucidum (Ling-Zhi) in healthy volunteers

Anesthesia and Analgesia

Volumn 101, Issue 2, 2005, Pages 423-426

  Kwok, Yung ^a   Ng, Kwok F J ^b,c   Li, Carina C F ^a   Lam, Clarence C K ^a   Man, Ricky Y K ^b  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

GANODERMA LUCIDUM EXTRACT; LING ZHI; PLACEBO;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FIBRINOGEN BLOOD LEVEL; GANODERMA LUCIDUM; HEMOSTASIS; HERBAL MEDICINE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY;

EID: 22944445777     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000155286.20467.28     Document Type: Article

References (26)

1. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287:337-44.
2. Yun TK. Update from Asia. Asian studies on cancer chemoprevention. Ann N Y Acad Sci 1999;889:157-92.
3. Shiao MS. Natural products of the medicinal fungus Ganoderma lucidum: occurrence, biological activities, and pharmacological functions. Chem Rec 2003;3:172-80.
4. Bao XF, Wang XS, Dong Q, et al. Structural features of immunologically active polysaccharides from Ganoderma lucidum. Phytochemistry 2002;59:175-81.
5. Hu H, Ahn NS, Yang X, et al. Ganoderma lucidum extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. Int J Cancer 2002;102:250-3.
6. Sliva D, Sedlak M, Slivova V, et al. Biologic activity of spores and dried powder from Ganoderma lucidum for the inhibition of highly invasive human breast and prostate cancer cells. J Altern Complement Med 2003;9:491-7.
7. Zhu M, Chang Q, Wong LK, et al. Triterpene antioxidants from ganoderma lucidum. Phytother Res 1999;13:529-31.
8. Lee A, Aun C, Chui PT. Use of Chinese herbal medicine in presurgical patients. Abstract Book of the Annual Scientific Meeting of Hong Kong College of Anaesthesiologists, November 2002, Hong Kong.
9. Su C, Shiao M, Wang C. Potentiation of ganodermic acid S on prostaglandin E(1)-induced cyclic AMP elevation in human platelets. Thromb Res 2000;99:135-45.
10. Su CY, Shiao MS, Wang CT. Differential effects of ganodermic acid S on the thromboxane A2-signaling pathways in human platelets. Biochem Pharmacol 1999;58:587-95.
11. Kawagishi H, Fukuhara F, Sazuka M, et al. 5′-deoxy-5′- methylsulphinyladenosine, a platelet-aggregation inhibitor from Ganoderma lucidum. Phytochemistry 1993;32:239-41.
12. Choi HS, Sa YS. Fibrinolytic and antithrombotic protease from Ganoderma lucidum. Mycologia 2000;92:545-52.
13. Law NL, Ng KF, Irwin MG, Man JS. Comparison of coagulation and blood loss during anaesthesia with inhaled isoflurane or intravenous propofol. Br J Anaesth 2001;86:94-8.
14. Tsen LC, Segal S, Pothier M, Bader AM. Alternative medicine use in presurgical patients. Anesthesiology 2000;93:148-51.
15. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001;286:208-16.
16. Leung JM, Dzankic S, Manku K, Yuan S. The prevalence and predictors of the use of alternative medicine in presurgical patients in five California hospitals. Anesth Analg 2001;93: 1062-8.
17. Norred CL, Brinker F. Potential coagulation effects of preoperative complementary and alternative medicines. Altern Ther Health Med 2001;7:58-67.
18. Gau JP, Lin CK, Lee SS, Wang SR. The lack of antiplatelet effect of crude extracts from ganoderma lucidum on HIV-positive hemophiliacs. Am J Chin Med 1990;18:175-9.
19. Cammerer U, Dietrich W, Rampf T, et al. The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery. Anesth Analg 2003;96:51-7.
20. Ereth MH, Nuttall GA, Klindworth JT, et al. Does the platelet-activated clotting test (HemoSTATUS) predict blood loss and platelet dysfunction associated with cardiopulmonary bypass? Anesth Analg 1997;85:259-64.
21. Kaufmann CR, Dwyer KM, Crews JD, et al. Usefulness of thrombelastography in assessment of trauma patient coagulation. J Trauma 1997;42:716-20.
22. Chau TN, Chan YW, Patch D, et al. Thrombelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding. Gut 1998;43:267-71.
23. Davis CL, Chandler WL. Thromboelastography for the prediction of bleeding after transplant renal biopsy. J Am Soc Nephrol 1995;6:1250-5.
24. Klein SM, Slaughter TF, Vail PT, et al. Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations. Anesth Analg 2000;91:1091-5.
25. Ruttmann TG, James MF. Pro-coagulant effect of in vitro haemodilution is not inhibited by aspirin. Br J Anaesth 1999;83: 330-2.
26. Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol 2002;9:407-15.